In Brief: Green tea
This article was originally published in The Tan Sheet
Executive Summary
Green tea: Epigallocathechin-3 gallate (EGCG), a ingredient in green tea, shown by Jerzy Jankun, PhD, et al., Medical College of Ohio, to inhibit urokinase, an enzyme whose increased presence indicates the increased risk of cancerous tumor spreading and growth, in a study appearing the June 5 issue of the science magazine Nature. "We postulate that the well-known anti-cancer activity of green tea is driven by the inhibition of uPA [urokinase], one of the most frequently overexpressed enzymes in human cancers," Jankun et al. state...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning